| Literature DB >> 26246660 |
L Putten1, R Bree2, P A Doornaert3, J Buter4, S E J Eerenstein5, D H F Rietveld3, D J Kuik6, C R Leemans5.
Abstract
Our objective was to evaluate recurrence patterns of hypopharyngeal and laryngeal carcinoma after chemoradiation and options for salvage surgery, with special emphasis on elderly patients. In a retrospective study all patients who underwent chemoradiation for hypopharyngeal and laryngeal carcinoma in a tertiary care academic center from 1990 through 2010 were evaluated. Primary outcome measures were the survival and complication rates of patients undergoing salvage surgery, especially in elderly patients. Secondary outcome measures were the predictors for salvage surgery for patients with locoregional recurrence after failed chemoradiotherapy. A review of the literature was performed. Of the 136 included patients, 60 patients had recurrent locoregional disease, of whom 22 underwent salvage surgery. Fifteen patients underwent a total laryngectomy with neck dissection(s) and 7 neck dissection without primary tumour surgery. Independent predictors for salvage surgery within the group of 60 patients with recurrent disease, were age under the median of 59 years (p = 0.036) and larynx vs. hypopharynx (p = 0.002) in multivariate analyses. The complication rate was 68% (14% major and 54% minor), with fistulas in 23% of the patients. Significantly more wound related complications occurred in patients with current excessive alcohol use (p = 0.04). Five-year disease free control rate of 35%, overall survival rate of 27% and disease specific survival rate of 35% were found. For the 38 patients who were not suitable for salvage surgery, median survival was 12 months. Patients in whom the tumour was controlled had a 5-year overall survival of 70%. In patients selected for salvage surgery age was not predictive for complications and survival. In conclusion, at two years follow-up after chemoradiation 40% of the patients were diagnosed with recurrent locoregional disease. One third underwent salvage surgery with 35% 5-year disease specific survival and 14% major complications. Older patients selected for salvage surgery had a similar complication rate and survival as younger patients.Entities:
Keywords: Chemoradiation; Complications; Elderly; Hypopharyngeal cancer; Laryngeal cancer; Review; Salvage surgery; Survival
Mesh:
Year: 2015 PMID: 26246660 PMCID: PMC4510934
Source DB: PubMed Journal: Acta Otorhinolaryngol Ital ISSN: 0392-100X Impact factor: 2.124
Patient characteristics of 60 patients with locoregional disease after chemoradiation.
| Variables | Number | Percentage (%) |
|---|---|---|
| Male | 51 | 85 |
| Female | 9 | 15 |
| T2 | 3 | 5 |
| T3 | 30 | 50 |
| T4 | 27 | 45 |
| N0 | 15 | 25 |
| N1 | 7 | 12 |
| N2a | 3 | 5 |
| N2b | 13 | 22 |
| N2c | 17 | 28 |
| N3 | 5 | 8 |
| Primary site | ||
| Hypopharynx | 35 | 58 |
| Larynx | 25 | 42 |
| Unresectable | 4 | 7 |
| Organ preservation approach | 56 | 93 |
| Chemoradiation schedule | ||
| Cisplatin IA | 2 | 3 |
| Cisplatin IV | 24 | 40 |
| Cisplatin/5-FU alternating | 14 | 24 |
| Cisplatin/5-FU sequential | 13 | 22 |
| Cetuximab | 5 | 8 |
| Cetuximab/TPF/Cisplatin or carboplatin | 2 | 3 |
Concurrent four intra-arterial cisplatin (150 mg/m2) infusions or three intravenous cisplatin (100 mg/m2) infusions. In both schemes patients were radiatedwith 70 Gy irradiation (6-7 weeks);
cisplatin 20 mg/kg and 5-FU 200 mg/kg intravenously in week 1, 4, 7, 10; radiotherapy in week 2, 3, 5, 6, 8, 9, total dose 60 Gy;
cisplatin 100 mg/kg and 5-FU 1000 mg/kg intravenously, 4 courses; followed by 7 weeks radiotherapy, total dose 70 Gy;
weekly cetuximab in combination with 7 weeks radiotherapy, total dose 70 Gy;
2-4 courses of TPF (Docetaxel, Platinum, Fluorouracil), followed by cisplatin or carboplatin with concurrent 70 Gy radiotherapy (7 weeks), in some patients cetuximab was given during this treatment.
Patient and salvage surgery characteristics.
| Patient | Gender | Age | T | N | Site | Recurrence | Larynx | ND | Reconstruction | Subsequent reconstruction |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 52 | 4 | 1 | Hypopharynx | Local | Laryngectomy | Bilateral | FRFF+PM | PM |
| 2 | M | 57 | 3 | 2b | Larynx | Regional | - | Unilateral | PC | |
| 3 | M | 64 | 4 | 0 | Larynx | Local | Laryngectomy | Unilateral | PM | |
| 4 | M | 63 | 4 | 0 | Larynx | Local | Laryngectomy | Bilateral | PM | PM |
| 5 | M | 62 | 4 | 0 | Larynx | Local | Laryngectomy | Unilateral | PM | |
| 6 | M | 59 | 3 | 2c | Hypopharynx | Regional | - | Bilateral | PM | |
| 7 | M | 41 | 3 | 0 | Hypopharynx | Local | Laryngectomy | Unilateral | PM | |
| 8 | M | 55 | 4 | 2c | Larynx | Local | Laryngectomy | Bilateral | PM | |
| 9 | M | 67 | 4 | 0 | Larynx | Local | Laryngectomy | Bilateral | PM | |
| 10 | M | 57 | 3 | 2b | Larynx | Local | Laryngectomy | Bilateral | PM | |
| 11 | M | 52 | 4 | 3 | Hypopharynx | Regional | - | Unilateral | PM | |
| 12 | M | 49 | 3 | 2a | Larynx | Regional | - | Unilateral | PC | $ |
| 13 | M | 54 | 4 | 2c | Larynx | Locoregional | Laryngectomy | Bilateral | PC | |
| 14 | M | 58 | 2 | 2b | Hypopharynx | Regional | - | Unilateral | PC | |
| 15 | M | 53 | 3 | 2c | Larynx | Local | Laryngectomy | Bilateral | PM | |
| 16 | M | 55 | 3 | 0 | Larynx | Local | Laryngectomy | Bilateral | PM | |
| 17 | M | 61 | 3 | 2c | Hypopharynx | Regional | - | Unilateral | PM | |
| 18 | F | 59 | 3 | 0 | Larynx | Local | Laryngectomy | Bilateral | PM | |
| 19 | M | 69 | 4 | 0 | Larynx | Local | Laryngectomy | Bilateral | PM | |
| 20 | F | 67 | 3 | 1 | Larynx | Local | Laryngectomy | Bilateral | PM | |
| 21 | M | 58 | 4 | 3 | Hypopharynx | Local | Laryngectomy | Bilateral | PM | |
| 22 | M | 64 | 3 | 2c | Larynx | Regional | - | Unilateral | PM |
1 year after ND: total salvage laryngectomy with FRFF and PM, followed by a second PM for complications. ND: neck dissection; PC: primary closed; PM: pectoralis major flap; FRFF: free radial forearm flap.
Postoperative complications for the total salvage surgery group, the group with an opened pharynx vs. the group with a closed pharynx.
| Complications | Total | Pharynx open | Pharynx closed | |||
|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |
| None | 7 | 31% | 4 | 27% | 3 | 43% |
| Wound healing | 13 | 59% | 9 | 59% | 4 | 57% |
| - Infection or dehiscence | 7 | 31% | 5 | 32% | 2 | 29% |
| - Haemorrhage | 1 | 5% | 0 | 0% | 1 | 14% |
| - Fistula | 5 | 23% | 4 | 27% | 1 | 14% |
| Pneumonia | 1 | 5% | 1 | 7% | 0 | 0% |
| Other | 1 | 5% | 1 | 7% | 0 | 0% |
| Total | 22 | 100% | 15 | 100% | 7 | 100% |
Fig. 1.Five-year survival after the last treatment (chemoradiation or salvage surgery).
Fig. 2.Survival after salvage surgery with model according to Tan et al. Comparison between patients with zero, one or two of the following presalvage predictors: stage IV vs. other stages and simultaneous locoregional vs. local or regional failure. No significant difference between the three groups was found.
Fig. 3.Survival after salvage surgery with model according to Tan et al. Comparison between patients initial stage IV vs. initial non-stage IV disease. A trend (p = 0.05) towards a worse survival for patients with initial stage IV disease was found.
Previous studies on complications and survival outcome in patients with salvage surgery after chemoradiotherapy for squamous cell carcinoma of the hypopharynx and larynx.
| Authors | Year | N | Site | Comp | Fistula | LR | OS | DSS | Remarks |
|---|---|---|---|---|---|---|---|---|---|
| Stoeckli | 2000 | 36 | L | 28% | 14% | 63% (5 y) | RT and CRT | ||
| Stoeckli | 2000 | 9 | H | 40% | 11% | 20% (5 y) | RT and CRT | ||
| Leon | 2001 | 28 | L | 21% | 17% | 57% (5 y) | endoresection | ||
| Weber | 2003 | 75 | L | ~59% | ~30% | 74% (2 y) | 69-71% (2 y) | ||
| Ganly | 2005 | 38 | L | 53% | 32% | ||||
| Clark | 2006 | 138 | L/H | 70% | 31% | 31% (5 y) | PT: none, RT, CRT | ||
| Fung | 2007 | 14 | L | 29% | Interposition graft. | ||||
| Furuta | 2008 | 34 | L | 47% wound | 24% | ||||
| Gil | 2009 | 18 | L | 39% | PL/TL, RT and CRT | ||||
| Patel | 2009 | 17 | L | 24% | CRT or RT? | ||||
| Relic | 2009 | 16 | L/H | 73% | 38% (3 y) | 1 PL | |||
| Tsou | 2010 | 48 | H | 58% | |||||
| Paleri | 2011 | >350 | L | 87% (2 y) | 83% (3 y) | 91% (2 y) | RT and CRT, PL | ||
| vd Putten | 2011 | 120 | L | 70% (5 y) | 50% (5 y) | 58% (5 y) | RT and CRT, TL | ||
| Klozar | 2012 | 208 | L/H | 34% | RT and CRT | ||||
| Sewnaik | 2012 | 24 | L/H | 92% | |||||
| Patel | 2013 | 359 | L/H | 27% | RT and CRT, primLE | ||||
| Li | 2013 | 100 | L | 70% (5 y) | 55-70% (5 y) | RT and CRT, survival | |||
| Basheeth | 2013 | 45 | L/H | 44% | Major complications, N0 | ||||
| Suzuki | 2013 | 24 | H | 33% | 50% (2 y) | ||||
| Sayles | 2014 | 33 st | L/H | 34% | |||||
| Timmermans | 2014 | 98 | L/H | 26% | RT and CRT, primLE | ||||
| Omura | 2014 | 42 | H | 40% (3 y) | RT and CRT, ICT | ||||
| Powell | 2014 | 45 | L/H | 22% | |||||
| Suslu | 2015 | 151 | L/H | 13% | RT and CRT, ICT | ||||
| Sassler | 1995 | 18 | HN | 61% major | 50% | Sequential CRT | |||
| Newman | 1997 | 17 | HN | 35% | 20% | ||||
| Lavertu | 1998 | 26 | HN | 46% | 4% | ||||
| Goodwin | 2000 | 109 | HN | 20% | 6% | Med 21.5 months | PT: surgery, RT, CRT (17%) | ||
| Goodwin | 2000 | 1633 | HN | 39% | 39% (5 y) | PT: surgery, RT, CRT | |||
| Agra | 2003 | 124 | HN | 78% (CRT) | PT: surgery, RT, CRT | ||||
| Gleich | 2004 | 48 | HN | 20% (5 y) | 15% (5 y) | Local recurrence | |||
| Taussky | 2005 | 17 | HN | 76% | 24% | 46% (3 y) | RT and CRT | ||
| Morgan | 2007 | 38 | HN | 11% | 5% | Local compl 23% | |||
| Encinas | 2007 | 26 | HN | 31% | Article not available | ||||
| Richey | 2007 | 38 | HN | 24% | 42% (2 y) | 27-60% | |||
| Tan | 2010 | 38 | HN | 63% | 43% (2 y) | ||||
| Inohara | 2010 | 30 | HN | 30% | 7% | 74-87% (3 y) | |||
| Esteller | 2011 | 32 | HN | 28% | 19% | 34% (5 y) | |||
| Simon | 2011 | 21 | HN | 33% | 10% | ||||
| Leon | 2015 | 24 | HN | 63% | 26%(5 y) | CRT | |||
| Present study | 22 | HN | 73% | 23% | 58% (5 y) | 27% (5 y) | 36% (5 y) | ||
| Davidson | 1999 | 34 | N | 38% | 12% | 37% CRT | |||
| Stenson | 2000 | 69 | N | 25% | 10% | ||||
| Newkirk | 2001 | 33 | N | 13 CRT,20 RT. | |||||
| Grabenbauer | 2003 | 56 | N | 25% | 4% | 44%(5 y) | 55% | Planned ND | |
| Kutler | 2004 | N | ~30% | Only abstract | |||||
| Brizel | 2004 | 52 | N | 8% major | 75% (4 y) | 77%(4 y) | Planned ND in N2-3. survival cCR | ||
| Frank | 2005 | 39 | N | 5% surgical | |||||
| vd Putten | 2007 | 61 | N | 79% (5 y) | 36% (5 y) | ||||
| Nouraei | 2008 | 41 | N | 95% (5 y) | 64% (5 y) | Survival hemineck | |||
| Vedrine | 2008 | 28 | N | 14% severe | |||||
| Christopoulos | 2008 | 32 | N | 13% | |||||
| Lango | 2009 | 65 | N | 18% | 5% | 55%CRT | |||
| Relic | 2009 | 12 | N | 8% | |||||
| Hillel | 2009 | 41 | N | 17% | |||||
| Bremke | 2009 | 25 | N | 24% | |||||
| Goguen | 2010 | 105 | N | 37% | |||||
| Robbins | 2012 | 30 | N | 60% (5 y) | SSND, CRT | ||||
| Yirbesoglu | 2013 | 44 | N | 71-73% (3 y) | 55-64% (3 y) |
Systematic review;
y: year; Com: complications, fistul: fistula, LR: locoregional control rate, OS: overall survival, DSS: disease specific survival, L: larynx, H: hypopharynx, HN: head and neck, N: neck, y: year, DFS: disease free survival, CRT: chemoradiotherapy, RT: radiotherapy, CT: chemotherapy, ND: neck dissection, PT: previous treatment, PL: partial laryngectomy, TL: total laryngectomy, primLE: primary laryngectomy, SSND: super selective neck dissection, st: studies, ICT: induction chemotherapy.
Comparison of pharyngocutaneous fistula in patients with salvage laryngectomy with and without flap reinforcement. In two studies, besides for reinforcement, the flap was also used to reconstruct pharyngeal defects .
| Authors | Year | N | Site | Flap | Fistula | WC | Fistula No flap | WC No flap | p | Remarks |
|---|---|---|---|---|---|---|---|---|---|---|
| Righini | 2005 | 60 | larynx | PMMF | 23% | 50% | 0.06 | Radiotherapy | ||
| Fung | 2007 | 41 | larynx | FVT | 29% | 0% | 30% | 15% | n.s. | |
| Patel | 2009 | 17 | larynx | PMF | 0% | 57% | 0.02 | (Chemo)radiotherapy | ||
| Gil | 2009 | 80 | larynx | PMMF | 27% | 24% | n.s. | PMMF 64% CRT, nonPMMF 25% CRT | ||
| Smith | 2003 | 223 | larynx | PMF | <1% | 23% | ||||
| Withrow | 2007 | 37 | larynx | FRFF | 18% | 50% | FRFF 41%CRT, nonFRFF 35%CRT | |||
| Patel | 2013 | 359 | larynx | PMF | 15% | 34% | 0.02 | (Chemo)radiotherapy | ||
| Powell | 2014 | 45 | larynx | FVT/PMF | 0% | 26% | ||||
| Sayles | 2014 | 33 studies | larynx | Onlay flap | 10% | 28% | 0.001 | (Chemo)radiotherapy | ||
| Paleri | 2014 | 591 | larynx | Pooled relative risk 0.63 (reduction one third compared to no flap) |
Systematic review;
WC: wound complications, p: p-value, PMMF: pectoralis major myofascial flap, FVT: free vascularised tissue, PMF: pectoralis major flap, FRFF: free radial forearm flap, CRT: chemoradiotherapy.